Table 3.

Venous RVA parameters in control and aSAH patients.

Parameter	Median [q1–q3]	n	p-value (vs. Control)	p-value (vs. aSAHf/u)
CRVE [MU]
Control	224 [218–236]	42	–	–
aSAHd0−4	196 [177–214]	32	<0.0001	0.2909
aSAHd5−15	194 [169–217]	53	<0.0001	0.4043
aSAHd16−23	191 [173–214]	23	<0.0001	0.2454
aSAHf/u	198 [181–209]	40	<0.0001	–
AVR
Control	0.85 [0.82–0.89]	42	–	–
aSAHd0−4	0.80 [0.73–0.89]	32	0.0396	0.8626
aSAHd5−15	0.82 [0.75–0.89]	53	0.0802	0.4305
aSAHd16−23	0.83 [0.75–0.86]	23	0.0986	0.7186
aSAHf/u	0.82 [0.75–0.87]	40	0.0050	–
MVD [%]
Control	3.9 [3.0–5.8]	42	–	–
aSAHd0−4	3.7 [2.9–4.7]	32	0.3179	0.1432
aSAHd5−15	4.1 [2.7–5.2]	53	0.4165	0.2388
aSAHd16−23	4.3 [2.6–5.4]	23	0.6356	0.5304
aSAHf/u	4.5 [3.4–5.4]	40	0.7270	–
tMVD [s]
Control	20.5 [19.0–22.0]	42	–	–
aSAHd0−4	22.0 [20.0–24.0]	32	0.1872	0.0235
aSAHd5−15	21.0 [19.0–22.5]	53	0.9903	0.0761
aSAHd16−23	22.0 [20.0–24.0]	23	0.4663	0.0110
aSAHf/u	19.0 [18.0–22.0]	40	0.2040	–
tMVD30 [s]
Control	7.0 [6.0–8.4]	42	–	–
aSAHd0−4	6.0 [5.0–8.0]	32	0.1269	0.6026
aSAHd5−15	7.0 [6.0–8.0]	53	0.7015	0.3347
aSAHd16−23	7.0 [7.0–8.0]	23	0.0720	0.1297
aSAHf/u	6.5 [5.5–8.0]	40	0.1530	–
AUCven [%*s]
Control	45.7 [31.3–62.2]	42	–	–
aSAHd0−4	41.3 [16.4–46.8]	32	0.0610	0.0205
aSAHd5−15	45.0 [27.5–60.8]	53	0.3833	0.1464
aSAHd16−23	44.5 [20.2–60.9]	23	0.3054	0.1853
aSAHf/u	52.4 [34.2–61.7]	40	0.6030	–

AUC_ven, venous area under the curve during flicker stimulation; AVR, retinal arterio-venous-ratio; CRVE, central retinal venous equivalent; f/u, follow-up (>6 weeks after ictus); MVD, maximum venous dilation; RVA, retinal vessel analysis; tMVD, time to maximum venous dilation; tMVD₃₀, time to 30% of maximum venous dilation. Bold values indicate p <0.05.